GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ironwood Pharmaceuticals Inc (NAS:IRWD) » Definitions » Current Ratio

Ironwood Pharmaceuticals (Ironwood Pharmaceuticals) Current Ratio : 0.84 (As of Dec. 2023)


View and export this data going back to 2010. Start your Free Trial

What is Ironwood Pharmaceuticals Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Ironwood Pharmaceuticals's current ratio for the quarter that ended in Dec. 2023 was 0.84.

Ironwood Pharmaceuticals has a current ratio of 0.84. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If Ironwood Pharmaceuticals has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.

The historical rank and industry rank for Ironwood Pharmaceuticals's Current Ratio or its related term are showing as below:

IRWD' s Current Ratio Range Over the Past 10 Years
Min: 0.84   Med: 4.74   Max: 30.58
Current: 0.84

During the past 13 years, Ironwood Pharmaceuticals's highest Current Ratio was 30.58. The lowest was 0.84. And the median was 4.74.

IRWD's Current Ratio is ranked worse than
83.55% of 1076 companies
in the Drug Manufacturers industry
Industry Median: 1.9 vs IRWD: 0.84

Ironwood Pharmaceuticals Current Ratio Historical Data

The historical data trend for Ironwood Pharmaceuticals's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ironwood Pharmaceuticals Current Ratio Chart

Ironwood Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Current Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.50 15.41 4.61 30.58 0.84

Ironwood Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 30.58 36.34 1.04 0.90 0.84

Competitive Comparison of Ironwood Pharmaceuticals's Current Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Ironwood Pharmaceuticals's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ironwood Pharmaceuticals's Current Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ironwood Pharmaceuticals's Current Ratio distribution charts can be found below:

* The bar in red indicates where Ironwood Pharmaceuticals's Current Ratio falls into.



Ironwood Pharmaceuticals Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Ironwood Pharmaceuticals's Current Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Current Ratio (A: Dec. 2023 )=Total Current Assets (A: Dec. 2023 )/Total Current Liabilities (A: Dec. 2023 )
=233.288/276.101
=0.84

Ironwood Pharmaceuticals's Current Ratio for the quarter that ended in Dec. 2023 is calculated as

Current Ratio (Q: Dec. 2023 )=Total Current Assets (Q: Dec. 2023 )/Total Current Liabilities (Q: Dec. 2023 )
=233.288/276.101
=0.84

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ironwood Pharmaceuticals  (NAS:IRWD) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Ironwood Pharmaceuticals Current Ratio Related Terms

Thank you for viewing the detailed overview of Ironwood Pharmaceuticals's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Ironwood Pharmaceuticals (Ironwood Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
100 Summer Street, Suite 2300, Boston, MA, USA, 02110
Ironwood Pharmaceuticals is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing innovative product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
Executives
Marla L Kessler director C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Andrew Davis officer: SVP, Chief Business Officer 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Sravan Kumar Emany officer: SVP, Chief Financial Officer 100 SUMMER ST, SUITE 2300, BOSTON MA 02109
Ronald Silver officer: Principal Accounting Officer 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Minardo John officer: Chief Legal Officer 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Thomas A Mccourt officer: Chief Commercial Officer C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Michael Shetzline officer: CMO,SVP,Head-Res&Drug 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Jason Rickard officer: SVP, Chief Operating Officer 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Mark G Currie officer: Chief Scientific Officer C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Julie Mchugh director C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Sarissa Capital Management Lp 10 percent owner 660 STEAMBOAT ROAD, GREENWICH CT 06830
Alexander J Denner director C/O SARISSA CAPITAL MANAGEMENT LP, 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Edward P Owens director C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Gina Consylman officer: Chief Accounting Officer C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Kilroy Conor officer: SVP, GC & Secretary 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110

Ironwood Pharmaceuticals (Ironwood Pharmaceuticals) Headlines

From GuruFocus

Ironwood Pharmaceuticals CEO Thomas Mccourt Sells 36,000 Shares

By GuruFocus Research GuruFocus Editor 05-25-2023

Ironwood Pharmaceuticals to Host First Quarter 2023 Investor Update Call

By Business Wire Business Wire 04-20-2023